The Japanese biotech company behind the newly approved Alzheimer's drug Leqembi isn't running a victory lap just yet. Eisai, with its partner Biogen (BIIB), knows the approval is another first step in what will soon be a competitive market. "What this disease state has needed for a long time has…
#leqembi #biib #alexscott #integrityateisai #yahoofinance #medicare #eisai #elililly #lly #lilly
Continue reading...